MBioLogix
MBioLogix is a privately held, Bangladesh-based company founded in 2012 and headquartered in Uttara, Dhaka, with 33 employees; its specific products, services, and customer base are not documented in the available data.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What MBioLogix does
MBioLogix is a Bangladesh-based private company headquartered in Uttara, Dhaka, that was founded in 2012 and currently reports a headcount of 33 employees. Beyond these firmographic attributes, the company's website (https://mbiologix.com/) was inaccessible at the time of data capture — returning only a verification/loading page — and no corroborating public information on products, services, customers, ownership, leadership, funding, or financials was available in the aggregated dataset. As a result, the company's specific industry, product surface, business model, and customer base cannot be reliably described from the inputs; the firm appears to be a small, privately held operating entity of roughly 13 years' standing.
Because product, technology, and revenue-model fields are empty in every source block, no inference about MBioLogix's underlying technology, platform architecture, or go-to-market mechanics is supportable. The company's name ("MBioLogix") linguistically suggests a molecular biology, life sciences, or biotechnology adjacency, but this is not confirmed by any documented product, patent, customer, or partnership signal in the input. Pricing models, publicly disclosed pricing, customer segments, value proposition, marketing channels, distribution channels, awards, patents, certifications, partnerships, integrations, and app/API presence are all unpopulated. For due diligence purposes, all of the above should be treated as data gaps requiring primary-source verification before any investment, partnership, or M&A decision is taken.
MBioLogix firmographics
Firmographics- Name
- MBioLogix
- Website
- https://mbiologix.com
- Company type
- Private
- Headcount range
- 11–50 employees
- Short description
- MBioLogix is a privately held, Bangladesh-based company founded in 2012 and headquartered in Uttara, Dhaka, with 33 employees; its specific products, services, and customer base are not documented in the available data.
- Ownership category
- akta.pro rank
MBioLogix industry classification
Industry- Product category
- Molecular Biology / Biotechnology Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
MBioLogix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations
MBioLogix product offering
Product offeringCore offering
MBioLogix's name indicates it operates in the molecular biology / biotechnology field. Specific products, services, and target customers could not be confirmed because the company website (mbiologix.com) displayed only a verification/loading page during extraction, providing no extractable descriptive content. The available signals suggest the company offers molecular biology-related products or services for life-science or research use.
Differentiator
Problem solved
Functional benefit
Companies that use MBioLogix
Customer profileIdeal customer profiles1 record
MBioLogix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MBioLogix competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Global leader in biologics CDMO services (mammalian and microbial); useful as the broad incumbent benchmark for what a scaled biologics CDMO offering looks like versus a small entity like MBioLogix.
- WuXi Biologics: Major China-headquartered biologics CDMO with global footprint across discovery, development, and manufacturing; relevant as a large, integrated biologics CDMO defining competitive cost and capacity dynamics.
- Samsung Biologics: Large-scale Korean biologics CDMO offering end-to-end development, manufacturing, and aseptic fill-finish services; sets the competitive benchmark for biologics CDMO scale and capability.
Regional players
- Square Pharmaceuticals: Bangladesh's largest pharmaceutical producer with biologics capabilities; comparable as a same-geography pharmaceutical/biologics player and useful benchmark for what scaled Bangladesh biologics operations look like.
- Globe Biotech: Bangladesh-based biopharmaceutical company developing vaccines, therapeutics, and biologics — directly comparable as a Bangladesh-situated biologics-focused entity of similar scale and regional cost structure.
- Incepta Pharmaceuticals: One of Bangladesh's largest pharma manufacturers with a biologics/vaccine portfolio; relevant because it demonstrates the scale ceiling and biologics ambition MBioLogix would need to clear, and operates in the same regulatory/cost environment.
- Beximco Pharmaceuticals: Bangladesh-headquartered finished-dose pharmaceutical and biologic manufacturer exporting globally; comparable as a Bangladesh pharma/biologics peer with a substantially larger scale.
Direct peers
- AGC Biologics: Mid-sized global CDMO offering mammalian and microbial biologics manufacturing, with a more focused footprint than mega-CDMO peers — directly comparable as a specialty biologics CDMO MBioLogix could evolve into.
Market position
Strengths2 records
Weaknesses2 records
Competitive moat1 record
Key risks3 records
Key highlights2 records
Customer concentration
MBioLogix social profiles
Digital presenceMBioLogix financial estimates
Financial estimateRevenue estimate
Valuation estimate
MBioLogix leadership team
Management profileNumber of profiles
MBioLogix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MBioLogix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MBioLogix
What does MBioLogix do?
MBioLogix's name indicates it operates in the molecular biology / biotechnology field. Specific products, services, and target customers could not be confirmed because the company website (mbiologix.com) displayed only a verification/loading page during extraction, providing no extractable descriptive content. The available signals suggest the company offers molecular biology-related products or services for life-science or research use.
When was MBioLogix founded?
MBioLogix was founded in -1. It employs 11 to 50 people.
Who are MBioLogix's main competitors?
Broad incumbents on record are Lonza Group, WuXi Biologics and Samsung Biologics. Regional players are Square Pharmaceuticals, Globe Biotech, Incepta Pharmaceuticals and Beximco Pharmaceuticals. AGC Biologics is listed as a direct peer.
Does MBioLogix have an API?
No public API is recorded for MBioLogix.
What industry is MBioLogix in?
MBioLogix's product category is Molecular Biology / Biotechnology Products. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2836.